Infantile haemangioma is the most common tumour of infancy, sometimes requiring treatment because of the risk of functional impairment or permanent scarring. Growth usually ceases by 12 months of age, and the tumour gradually regresses. In 2008, a review of all patients previously seen in seven international treatment centres identified only five children in whom any haemangioma growth was seen beyond 2 years of age, and none beyond 4 years.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Brandling-Bennett HA, Baselga E, Lucky AW, et al. Infantile hemangiomas with unusually prolonged growth phase. Arch Dermatol 2008; 144: 1632-1637.
- 2. Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372: 735-746.
- 3. Phillips RJ, Penington AJ, Bekhor PS, Crock CM. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. J Paediatr Child Health 2012; 48: 902-906.
- 4. Shah SD, Baselga E, McCuaig C, et al. Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics 2016; 137: e20151754.
- 5. Munabi NC, England RW, Edwards AK, et al. Propranolol targets hemangioma stem cells via cAMP and mitogen-activated protein kinase regulation. Stem Cells Transl Med 2016; 5: 45-55.
No relevant disclosures.